PureTech Health Unit Akili's AKL-T01 Study Achieves Primary Endpoint

(Alliance News) - PureTech Health PLC on Wednesday said its affiliate Akili reported top-line ...

Alliance News 15 January, 2020 | 1:26PM
Email Form

(Alliance News) - PureTech Health PLC on Wednesday said its affiliate Akili reported top-line results of its multi-site open-label study to evaluate the effects of AKL-T01 in children with attention deficit hyperactivity disorder.

The FTSE 250-listed biotechnology investor said the study achieved its predefined primary efficacy outcome, demonstrating a statistically significant improvement in the attention deficit hyperactivity disorder impairment rating scale from baseline after one month of treatment.

"We are pleased with these new results as they provide additional support for AKL-T01 in paediatric attention deficit hyperactivity disorder - both as a monotherapy and in combination with stimulant medications," said PureTech Chief Innovation Officer Eric Elenko.

PureTech shares were trading 0.7% higher in London on Wednesday at 274.00 pence each.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
PureTech Health PLC 274.00 GBX 4.18 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies